Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03421327 · ClinicalTrials.gov registry record
Genetic Risk: Whether, When, and How to Tell Adolescents
A clinical trial of Huntington Disease and Hereditary Breast and Ovarian Cancer, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 85
- Enrollment target
- 1
- Study location
NCT03421327: Completed study of Huntington Disease and Hereditary Breast and Ovarian Cancer, sponsored by Johns Hopkins University.
NCT03421327 is a study of Huntington Disease and Hereditary Breast and Ovarian Cancer that has completed, run by Johns Hopkins University. The registered enrollment target is 85 participants, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03421327, a study of Huntington Disease and Hereditary Breast and Ovarian Cancer, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for Huntington's Disease, parent/child pairs at risk for hereditary cancer, and genetic counselors.
Primary Outcome
Qualitative interview performed at one occasion where the patient describes when and how genetic risk information was disclosed to minor as well as perspectives from both parent and child.
Conditions Studied
Study Locations (1)
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-12-31 |
What the finished NCT03421327 record still lists
NCT03421327 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (87% lower).
The record links to 5 conditions, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03421327 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03421327 about?
NCT03421327 is a clinical study titled "Genetic Risk: Whether, When, and How to Tell Adolescents". This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for Huntington's Disease, parent/child pairs at risk for hereditary cancer, and g...
What is the current status of trial NCT03421327?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-09-01. Estimated completion is 2018-12-31.
What conditions does trial NCT03421327 study?
This clinical trial studies the following conditions: Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome.
Who is sponsoring clinical trial NCT03421327?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03421327 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03421327's enrollment target sits among peer trials
85 21st of 35 higher than 15 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI